+52.1%
CSX vs MRNA
+444.4%
-392.3%
-11.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -3.4% | +2.1% | -1.3% |
| 7D | -0.6% | -10.1% | +9.5% | -0.5% |
| 30D | -3.2% | +126.7% | -130.0% | -4.6% |
| 3M | +2.6% | +184.1% | -181.5% | -0.6% |
| 6M | +19.8% | +143.3% | -123.5% | +16.9% |
| YTD | +34.7% | +359.9% | -325.2% | +24.8% |
| 1Y | +52.1% | +454.2% | -402.0% | +37.4% |
| All | +52.1% | +444.4% | -392.3% | +37.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling